Defining Recurrent Disease With Axumin™

Diagnosing and Monitoring Recurrent Disease in Prostate Cancer Patients Using a Positron Emission Tomography Radiotracer (Axumin™)

This project seeks to use advanced imaging (specifically, positron emission tomography/computed tomography [PET/CT]) to detect, locate, and characterize recurrent disease in the setting of patients with prostate cancer.

Study Overview

• Status: Unknown
• Conditions: Prostate Cancer; Prostate Adenocarcinoma
• Intervention / Treatment: Drug: Casodex, Axumin; Radiation: Salvage Radiation, Axumin

Detailed Description

This protocol details the study design for patients with prostate cancer (PCa) who have failed primary treatment with radical prostatectomy, and now have rising PSA as indicated by a recent PSA blood draw value > 0.1 ng/ml. Patients fitting our inclusion criteria for the study, will receive an Axumin scan as part of their standard of care (SOC) treatment. If the SOC scan is positive, patients under this protocol will either subsequently receive hormone therapy OR salvage radiation therapy (not both concurrently). Patient response to therapy will be assessed with serial Axumin scans identifying additional lesions present at 3 months, 6 months, and 12 months (1 year) post-therapy, with the latter time point being our endpoint of the study.

The study aims are as follows:

1. The investigators would like to understand the hormonal therapy response based on Axumin scans administered over a time course of 3 months, 6 months, and 12 months post-hormone therapy treatment.
2. The investigators would like to understand the salvage radiotherapy response based on Axumin scan results incorporated into radiation treatment planning over a time course of 3 months, 6 months, and 12 months post-salvage radiation treatment.

• Study Type: Observational
• Enrollment (Anticipated): 20

Contacts and Locations

Study Locations

• United States
  • California
    • Irvine, California, United States, 92619
      • Recruiting
      • Kenneth Tokita
      • Contact: Kenneth M Tokita, MD; Phone Number: 949-417-1100; Email: kmtokita@ccoi.org

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Male

• Sampling Method: Non-Probability Sample

Study Population

Men with recurrent prostate cancer.

Description

Inclusion Criteria:

General requirements:

1. Karnofsky performance status of >50 (or ECOG/WHO equivalent).
2. Age > 18.
3. Ability to understand a written informed consent document, and the willingness to sign it.
4. History of histologically confirmed adenocarcinoma of the prostate and underwent radical prostatectomy for primary treatment with curative intent.
5. Men diagnosed with recurrent/persistent prostate cancer disease following radical prostatectomy based on a detectable or rising PSA value ≥ 0.1 ng/ml.
6. Positive commercial standard of care (SOC) Axumin scan at time of restaging disease.
7. Patients should not have been previously treated for biochemical recurrence (BCR) (i.e., this is the first diagnosis for BCR.
8. Language proficiency in English, Spanish, Japanese, Korean, Vietnamese. Our office has translators to coherently translate the consent documents to patients.

Inclusion criteria specific for patients on response to ADT study:

1. Ability to tolerate androgen deprivation therapy (Casodex and Lupron) indefinitely.
2. Been off ADT for minimum of 3 months.
3. Ability to receive a possible of 4 Axumin PET/CT scans within a year.

Inclusion criteria specific for patients on response to salvage radiotherapy study:

1. Considering salvage radiotherapy.
2. Ability to tolerate salvage radiation therapy for 8 weeks.

Exclusion Criteria:

General requirements:

1. Patients not capable of getting PET study due to weight, claustrophobia, allergic reaction, and/or inability to lay still for the duration of the exam.
2. Women and children.
3. Men currently on or seeking primary treatment (surgery or radiation) for prostate cancer.
4. History of bilateral orchidectomy.
5. Neoadjuvant chemotherapy or radiation therapy prior to prostatectomy. This includes focal ablation techniques (HiFu).
6. Ongoing treatment with any systemic therapy intended for the treatment of prostate cancer (e.g., antiandrogen or LHRH agonist or antagonist).
7. Prior history of any other malignancy within the last 2 years, other than skin basal cell or cutaneous superficial squamous cell carcinoma that has not metastasized and superficial bladder cancer.

Exclusion criteria specific for patients on response to ADT study:

1. Being considered for salvage radiotherapy.
2. Androgen deprivation therapy (ADT) in the past 3 months.

Exclusion criteria specific for patients on response to salvage radiotherapy study:

1. Currently on ADT or on ADT within the past 3 months.

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Hormone Therapy Cohort; Post-radical prostatectomy patients fitting our inclusion criteria, including rising PSA > 0.1 ng/ml, a positive SOC Axumin scan, and a patients not having received hormonal therapy for a minimum of 3 months, will receive hormonal therapy in the form of Casodex for 2 weeks, followed by Lupron indefinitely. Patients will then receive serial Axumin scans up to 1 year post-therapy.	Drug: Casodex, Axumin; Patients will receive hormone therapy if Axumin positive area appears.; Other Names: Lupron
Salvage Radiotherapy Cohort; Post-radical prostatectomy patients fitting our inclusion criteria, including rising PSA > 0.1 ng/ml, not concurrently on androgen deprivation therapy (ADT) and/or received ADT in the past 3 months, and a positive SOC Axumin scan, will receive salvage radiation therapy according to the following protocol. External beam radiation therapy will be delivered in the form of high-dose intensity modulated radiation therapy (IMRT). A total prescribed dose of 72 Gy will be delivered in 40 fractions over 8 weeks. For the first 25 fractions, the clinical target volume (CTV) is defined as the residual prostatic bed, plus internal/external iliac nodes. For the subsequent 15 fractions the CTV is defined as the residual prostatic bed plus margin. As part of SOC, the radiation fields will incorporate the Axumin positive areas into treatment planning objectives. Patients will then receive serial Axumin scans up to 1 year post-therapy.	Radiation: Salvage Radiation, Axumin; Patients will receive salvage radiation therapy if Axumin positive area appears.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of baseline Axumin uptake	Utilizing standard uptake values (SUV) from the tumor origin, serial Axumin SUV values will be calculated as a percentage of the baseline SUV value.	2019-2020

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
PSA blood draw	Prostate specific antigen (PSA) values expressed as [ng/ml] will be serially drawn at each time of the Axumin scan to correlate with percentage of baseline SUV value.	2019-2020

Collaborators and Investigators

• Sponsor: Cancer Center of Irvine

Study record dates

Study Major Dates

• Study Start (Anticipated): July 1, 2019
• Primary Completion (Anticipated): September 30, 2020
• Study Completion (Anticipated): December 30, 2020

Study Registration Dates

• First Submitted: June 18, 2019
• First Submitted That Met QC Criteria: June 22, 2019
• First Posted (Actual): June 25, 2019

Study Record Updates

• Last Update Posted (Actual): June 25, 2019
• Last Update Submitted That Met QC Criteria: June 22, 2019
• Last Verified: June 1, 2019

More Information

Terms related to this study

• Keywords: prostate cancer; Axumin
• Additional Relevant MeSH Terms: Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Genital Neoplasms, Male; Prostatic Diseases; Prostatic Neoplasms; Physiological Effects of Drugs; Antineoplastic Agents; Hormones, Hormone Substitutes, and Hormone Antagonists; Hormone Antagonists; Androgen Antagonists; Bicalutamide
• Other Study ID Numbers: 2018/12/7

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes